COVID19: EMA green-lights Omicron adapted booster jabs

The European Medicines Agency (EMA) has recommended using two COVID-19 vaccines adapted against the Omicron variant by Pfizer/BioNTech and Moderna. The so-called Comirnaty Original/Omicron BA.1 (from Pfizer/BioNTech) and Spikevax Bivalent Original/Omicron BA.1

COVID19: EMA looks at improved Moderna vaccine

The European Medicines Agency (EMA) has started a rolling review for a Spikevax (Moderna) vaccine adapted to provide better protection against specific variants of SARS-CoV-2. The Ministry of Health said the review

COVID19: EMA reviews new Valneva vaccine

The European Medicines Agency (EMA) announced its human medicines committee (CHMP) started a rolling review of VLA2001, a COVID-19 vaccine developed by French company Valneva. The CHMP’s decision to start the rolling

COVID19: EMA fast-tracks evaluating Novavax vaccine

The European Medicines Agency (EMA) has started evaluating an application for conditional marketing authorisation for Novavax’s COVID-19 vaccine, Nuvaxovid, the agency announced. The EU assessment will proceed under an accelerated timeline. An

EMA reviews anti-COVID-19 pill for early use

The European Medicines Agency will begin reviewing data on game-changing antiviral pill molnupiravir, produced by US company MSD, against COVID-19, to support countries who want to use this medicine before receiving final